PYC Therapeutics Advances 60µg Dose into Multi-Dose Trial for Rare Eye Disease
PYC Therapeutics receives approval to advance PYC-001 into multi-dose study for blinding eye disease
PYC Therapeutics has announced that the Safety Review Committee (SRC) governing its Phase 1 study has approved progression of the 60 microgram dose of PYC-001 into a Multiple Ascending Dose (MAD) study for Autosomal Dominant Optic Atrophy (ADOA). The SRC reviewed 4-week safety and tolerability data before clearing the dose level for multi-dose evaluation. ADOA is a genetic blinding condition affecting 1 in 35,000 people globally, with no approved treatment options currently available.
The clinical milestone de-risks the asset and positions the Company to generate efficacy data, the next critical value inflection point for the ADOA program.
When big ASX news breaks, our subscribers know first
What is Autosomal Dominant Optic Atrophy and why does it matter to investors?
Autosomal Dominant Optic Atrophy is a genetic condition that causes progressive vision loss due to degeneration of the optic nerve. PYC-001 is designed to address the underlying genetic cause of ADOA rather than merely managing symptoms.
Key ADOA facts:
- Prevalence: 1 in 35,000 people
- Cause: Genetic mutations affecting the optic nerve
- Current treatments: None approved
Rare diseases with no treatment options often receive expedited regulatory review and premium pricing. PYC is targeting a defined patient population with a precision medicine approach, offering potential orphan drug designation and clear regulatory pathways to commercialisation.
Phase 1/2 study design positions PYC-001 for registrational pathway
The study is progressing from Single Ascending Dose (SAD) evaluation to Multiple Ascending Dose (MAD) assessment. The 60 microgram cohort now joins existing 10 microgram and 30 microgram cohorts in the MAD study.
The trial is evaluating safety, tolerability, efficacy, and an exploratory biomarker (Flavoprotein Fluorescence) across n=3 patients per cohort. Dosing intervals include Q8W (every 8 weeks) and Q12W (every 12 weeks). The clinical objective is to establish proof-of-concept before advancing to a global registrational trial (ClinicalTrials.gov identifier: NCT06970106).
| Dose Level | Dosing Interval | Patients per Cohort | Status |
|---|---|---|---|
| 10 micrograms | Q8W, Q12W | n=3 | Ongoing |
| 30 micrograms | Q8W, Q12W | n=3 | Ongoing |
| 60 micrograms | Q8W, Q12W | n=3 | Approved for MAD |
The structured dose escalation approach reduces regulatory risk and builds a comprehensive safety database to support future approval applications.
The next major ASX story will hit our subscribers first
Data catalysts scheduled through 2026 and 2027
Safety and efficacy outcomes from the MAD study will be presented throughout 2026 and 2027. The ultimate goal is to generate clinical proof-of-concept data that supports progression into a global registrational trial, directed towards a New Drug Application for PYC-001 in ADOA.
PYC has three clinical-stage programs, all enabled by the Company’s proprietary RNA delivery platform designed to enhance the potency of precision medicines within the RNA therapeutic class.
Development pathway milestones:
- SAD study clearance (completed)
- MAD study initiation (current phase)
- Clinical proof-of-concept generation (2026-2027)
- Global registrational trial (subject to regulatory approval)
- New Drug Application submission
Multiple near-term data catalysts provide regular newsflow and potential re-rating opportunities as clinical evidence accumulates.
Management perspective on clinical progress
The announcement was approved by the Board of PYC Therapeutics. The SRC’s approval to progress the 60 microgram dose into the MAD study represents external validation of the safety profile established during the 4-week follow-up period in the SAD study.
PYC Therapeutics has cleared a critical safety hurdle by progressing the 60 microgram dose of PYC-001 into multi-dose evaluation for ADOA. The Company is now a clinical-stage rare disease developer with multiple programs and near-term data catalysts that could support registration-enabling studies. Investors should monitor MAD study updates through 2026 and 2027 as the Company builds the clinical evidence base required to support a New Drug Application.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare and biotech news within minutes of release, complete with expert analysis. Click the “Free Alerts” button at Big News Blast to get real-time alerts the moment clinical trial results, regulatory approvals, and market-moving announcements hit the ASX.